专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

101. 发明授权

EP1467979B1 FUSED HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION 有权
标题翻译：简明杂环化合物和它们的类似物; 受体核激素的功能调节剂
公开(公告)号：EP1467979B1
公开(公告)日：2008-08-13
申请号：EP02798550.6
申请日：2002-12-18
申请人： Bristol-Myers Squibb Company
发明人： SALVATI, Mark, E. , BALOG, James, Aaron , PICKERING, Dacia, A. , ZHU, Hong
IPC分类号： C07D275/06 , C07D513/18 , A61P35/00 , A61K31/425
CPC分类号： C07D209/74 , C07D209/76 , C07D231/54 , C07D275/06
摘要： Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

102. 发明公开

EP1937259A1 HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS 有权
标题翻译：六氢CYCLOHEPTAPYRAZOL，大麻素调节
公开(公告)号：EP1937259A1
公开(公告)日：2008-07-02
申请号：EP06814802.2
申请日：2006-09-18
申请人： Janssen Pharmaceutica NV
发明人： LIOTTA, Fina , PAN, Meng , XIA, Mingde , WACHTER, Michael, P. , LU, Huajun
IPC分类号： A61K31/416 , C07D231/54 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , A61P3/00 , A61P25/00
CPC分类号： C07D403/06 , C07D231/54 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12
摘要： This invention is directed to a hexahydro-cycloheptapyrazole cannabinoid modulator compound of formula (I): and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.

103. 发明公开

EP1924562A2 PYRAZOLONE DERIVATIVES 审中-公开
标题翻译：吡唑啉酮
公开(公告)号：EP1924562A2
公开(公告)日：2008-05-28
申请号：EP06792909.1
申请日：2006-08-21
申请人： F.HOFFMANN-LA ROCHE AG
发明人： AMREIN, Kurt , HUNZIKER, Daniel , KUHN, Bernd , MAYWEG, Alexander V. , NEIDHART, Werner
IPC分类号： C07D231/20 , C07D231/22 , C07D231/26 , C07D487/04 , C07D471/04 , C07D231/56 , C07D231/54
CPC分类号： C07D231/20 , C07D231/22 , C07D231/26 , C07D231/54 , C07D231/56 , C07D471/04 , C07D487/04
摘要： Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R4 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.

104. 发明公开

EP1917247A1 4,5-DIHYDR0-1H-PYRAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS 审中-公开
标题翻译： 4,5-二氢-1H-吡唑衍生物，它们的生产和它们作为药物
公开(公告)号：EP1917247A1
公开(公告)日：2008-05-07
申请号：EP06776261.7
申请日：2006-07-15
申请人： Laboratorios del Dr. Esteve S.A.
发明人： BUSCHMANN, Helmut , TORRENS JOVER, Antonio , MAS PRIO, Jose , QUINTANA RUIZ, Jordi, Ramon , YENES MINGUEZ, Susana
IPC分类号： C07D231/06 , C07D403/12 , C07D409/04 , A61K31/4155 , A61K31/415 , A61P3/04 , A61P25/30 , A61P35/00
CPC分类号： C07D231/54 , C07D231/06 , C07D401/12 , C07D403/12 , C07D409/04
摘要： The present invention relates to 4-substituted pyrazoline compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

105. 发明公开

EP1910339A2 AZEPANE- OR AZOCANE-SUBSTITUTED PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS 审中-公开
标题翻译：氮杂环庚OR AZOCANSUBSTITUIERTE吡唑啉，生产及其作为药物
公开(公告)号：EP1910339A2
公开(公告)日：2008-04-16
申请号：EP06762650.7
申请日：2006-07-17
申请人： Laboratorios del Dr. Esteve S.A.
发明人： TORRENS JOVER, Antonio , YENES MÍNGUEZ, Susana
IPC分类号： C07D403/12 , C07D403/06 , A61K31/4155 , A61K31/55 , A61P3/04 , A61P25/00 , A61P35/00
CPC分类号： C07D231/54 , C07D231/06 , C07D401/12 , C07D403/12 , C07D409/04
摘要： The present invention relates to Azepane- or Azocane- substituted substituted pyrazoline compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals

106. 发明公开

EP1910301A2 CYCLOALKANE-SUBSTITUTED PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS 审中-公开
标题翻译： CYCLO的烷取代吡唑啉，生产及其作为药物
公开(公告)号：EP1910301A2
公开(公告)日：2008-04-16
申请号：EP06762651.5
申请日：2006-07-17
申请人： Laboratorios del Dr. Esteve S.A.
发明人： TORRENS JOVER, Antonio , YENES MINGUEZ, Susana
IPC分类号： C07D231/06 , A61K31/415 , A61P3/04 , A61P25/00 , A61P35/00
CPC分类号： C07D231/54 , C07D231/06 , C07D401/12 , C07D403/12 , C07D409/04
摘要： The present invention relates to Cycloalkane- substituted substituted pyrazoline compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

107. 发明公开

EP1832589A1 Inhibitors of cyclin-dependent kinases,compositions and uses related thereto 审中-公开
标题翻译： CyclinabhängigeKinasehemmer，Zusammensetzungen und damit verbundene Verwendungen
公开(公告)号：EP1832589A1
公开(公告)日：2007-09-12
申请号：EP07008359.7
申请日：2002-10-15
申请人： GPC Biotech Inc. , GPC Biotech AG
发明人： Becker, Frank
IPC分类号： C07D487/04 , C07D231/54 , C07F9/6561 , C07F9/6503 , C07D403/12 , A61K31/519 , A61K31/416 , A61K31/675 , A61P35/00 , A61P31/12
CPC分类号： C07F9/6561 , C07D231/54 , C07D403/12 , C07D487/04 , C07F9/65583
摘要： The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.
摘要翻译：本发明涉及新的细胞周期蛋白依赖性激酶抑制剂（cdks），具体而非排他地作为cdk /细胞周期蛋白复合物的抑制剂。如本文所述，本发明的抑制剂能够抑制细胞周期机制，因此可用于调节细胞周期进程，最终控制细胞生长和分化。这样的化合物可用于治疗患有与过量细胞增殖相关的疾病的受试者。

108. 发明公开

EP1709004A2 PYRROLE AND PYRAZOLE DAAO INHIBITORS 审中-公开
标题翻译：吡咯和吡唑ALS抑制剂DAAO
公开(公告)号：EP1709004A2
公开(公告)日：2006-10-11
申请号：EP04815792.9
申请日：2004-12-28
申请人： Sepracor Inc.
发明人： FANG, Q., Kevin , HOPKINS, Seth , JONES, Steven
IPC分类号： C07D231/54
CPC分类号： C07D231/56 , C07D207/34 , C07D209/42 , C07D209/44 , C07D231/14 , C07D231/16 , C07D231/54 , C07D491/04
摘要： Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof: (I) wherein R1 and R2 are independently selected from hydrogen, halo, nitro, alkyl, acyl, alkylaryl, and XYR5; or R1 and R2, taken together, form a 5, 6, 7 or 8-membered substituted or unsubstituted carbocyclic or heterocyclic group; X and Y are independently selected from O, S, NH, and (CR6R7)n; R3 is hydrogen, alkyl or M+; M is aluminum, calcium, lithium, magnesium, potassium , sodium , zinc ion or a mixture thereof; Z is N or CR4; R4 is from selected from hydrogen, halo, nitro, alkyl, alkylaryl, and XYR5; R5 is selected from aryl, substituted aryl, heteroaryl and substituted heteroaryl; R6 and R7 are independently selected from hydrogen and alkyl; n is an integer from 1 to 6; at least one of R1, R2 and R4 is other than hydrogen; and at least one of X and Y is (CR6R7)n. D-serine or cycloserine may be coadministered along with the compound of formula (I).

109. 发明公开

EP1693369A1 PROTEIN MODIFIER PRODUCTION INHIBITOR 审中-公开
标题翻译：抑制剂制剂EINER PROTEINMODIFIZIERENDEN SUBSTANZ
公开(公告)号：EP1693369A1
公开(公告)日：2006-08-23
申请号：EP04819933.5
申请日：2004-12-03
申请人： TOKAI UNIVERSITY EDUCATIONAL SYSTEM , Miyata, Toshio , Kurokawa, Kiyoshi
发明人： MIYATA, Toshio , KUROKAWA, Kiyoshi
IPC分类号： C07D231/22
CPC分类号： C07D491/04 , C07D231/22 , C07D231/26 , C07D231/54
摘要： [PLOBLEMS] To provide a inhibitor of protein modification products formation capable of inhibiting of vitamin B6 deficiency disease as a side effect, especially a renal protective agent. [MEANS FOR SOLVING PROBLEMS] There is provided a use, as an active ingredient, of any of free or salt-form compounds of either of the formulae: (I) (II) [wherein R1 is substituted or unsubstituted aromatic ring; and each of R2, R3 and R4 is a hydrogen atom or monovalent organic group, or alternatively R2 and R3 cooperate to form a condensed ring or R3 and R4 cooperate to represent a divalent organic group, provided that R3 and R4 are not simulataneously hydrogen atoms].
摘要翻译：提供能够抑制维生素B6缺乏症作为副作用的蛋白质修饰产物形成抑制剂，特别是肾保护剂。用于解决问题的手段作为活性成分，提供以下任一式的任何游离或盐形式的化合物：（I）（II）[其中R 1为取代或未取代的芳环; R 2，R 3和R 4各自为氢原子或一价有机基团，或者R 2和R 3相互配位以形成稠合环，或者R 3和R 4合作表示二价有机基团，条件是R 3和R 4不是同时氢原子 ]。

110. 发明公开

EP1479670A4 NOVEL FUSED RING INDAZOLE COMPOUNDS 有权
标题翻译：新吲唑稠环
公开(公告)号：EP1479670A4
公开(公告)日：2006-03-08
申请号：EP03703358
申请日：2003-02-21
申请人： EISAI CO LTD
发明人： OHI NORIHITO , SATO NOBUAKI , KOHMURA NAOHIRO
IPC分类号： C07D231/56 , A61K31/416 , A61K31/4439 , A61K31/55 , A61P1/08 , A61P9/10 , A61P13/02 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/36 , A61P27/16 , A61P29/00 , A61P37/06 , A61P39/00 , A61P43/00 , C07D231/54 , C07D401/12 , C07D405/12 , C07D487/06
CPC分类号： A61K31/55 , A61K31/416 , A61K31/4439 , C07D231/54 , C07D401/12 , C07D405/12 , C07D487/06
摘要： It is intended to provide novel fused ring indazole compounds having an excellent JNK inhibitory effect. More specifically, compounds represented by the following general formula, salts thereof or hydrates of the same are provided: (I) wherein Z11 and Z12 independently represent each carbonyl, methylene, etc.; ---- represents a double or single bond; R1a represents hydrogen, etc.; the ring A represents a benzene ring, a naphthalene ring or a 5- to 10-membered heteroaryl group; and R2a, R2b and R2c independently represent each (1) hydrogen, (2) halogeno, (3) nitro, etc.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式